Clinical Trial

A Trial of Inebilizumab in Participants With Autoimmune Hepatitis

Study acronym: MERCURY
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main objectives of this trial are to evaluate the safety and tolerability of inebilizumab in participants with autoimmune hepatitis (AIH) (Part 1) and to evaluate the efficacy of inebilizumab on AIH disease activity and glucocorticoid (GC) use in the management of AIH (Part 2).
Protocol Amendment History 1 change
notable Trial sites expanded: 0 -> 12 locations 2026-08-15
Trial Details
NCT Number NCT07598825
Lead Sponsor Amgen
Conditions Autoimmune Hepatitis, AIH
Enrollment 180 participants
Start Date 2026-09-07
Primary Completion 2031-07-30 (estimated)
Study Completion 2034-02-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-14